Adoptive T-cell therapy for fungal infections in haematology patients

Clinical and Translational Immunology

Volumn 4, Issue 8, 2015, Pages

  Deo, Shivashni S ^a,b   Gottlieb, David J ^a,b,c  

^a WESTMEAD HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84990240811     PISSN: None     EISSN: 20500068     Source Type: Journal    
DOI: 10.1038/cti.2015.16     Document Type: Review

References (69)

1. Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010; 50: 1091–1100.
2. Sun Y, Meng F, Han M, Zhang X, Yu L, Huang H et al. Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in China: a multicenter prospective observational study. Biol Blood Marrow Transplant 2015; 21: 1117–1126.
3. Neofytos D, Horn D, Anaissie E, Steinbach W, Olyaei A, Fishman J et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 2009; 48: 265.
4. Simms-Waldrip T, Rosen G, Nielsen-Saines K, Ikeda A, Brown B, Moore T. Invasive fungal infections in pediatric hematopoietic stem cell transplant patients. Scand J Infect Dis 2015; 47: 218–224.
5. De La Rosa GR, Champlin RE, Kontoyiannis DP. Risk factors for the development of invasive fungal infections in allogeneic blood and marrow transplant recipients. Transpl Infect Dis 2002; 4: 3–9.
6. Hale KA, Shaw PJ, Dalla-Pozza L, MacIntyre CR, Isaacs D, Sorrell TC. Epidemiology of paediatric invasive fungal infections and a case-control study of risk factors in acute leukaemia or post stem cell transplant. Br J Haematol 2010; 149: 263–272.
7. Geddes M, Storek J. Immune reconstitution following hematopoietic stem-cell transplantation. Best Pract Res Clin Haematol 2007; 20: 329–348.
8. Wiederhold NP, Lewis RE, Kontoyiannis DP. Invasive aspergillosis in patients with hematologic malignancies. Pharmacotherapy 2003; 23: 1592–1610.
9. Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, Martino B et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006; 91: 1068–1075.
10. Bhatt VR, Viola GM, Ferrajoli A. Invasive fungal infections in acute leukemia. Ther Adv Hematol 2011; 2: 231–247.
11. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909–917.
12. Riwes MM, Wingard JR. Diagnostic methods for invasive fungal diseases in patients with hematologic malignancies. Exp Rev Hematol 2012; 5: 661–669.
13. Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Ellis D, Tullio V et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol 2010; 48: 1366–1377.
14. Pfaller MA, Diekema DJ, Sheehan DJ. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev 2006; 19: 435–447.
15. Howard SJ, Cerar D, Anderson MJ, Albarrag A, Fisher MC, Pasqualotto AC et al. Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis 2009; 15: 1068–1076.
16. Snelders E, van der Lee HA, Kuijpers J, Rijs AJ, Varga J, Samson RA et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med 2008; 5: e219.
17. Denning DW, Venkateswarlu K, Oakley KL, Anderson MJ, Manning NJ, Stevens DA et al. Itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 1997; 41: 1364–1368.
18. Chrenkova V, Hubacek P, Sedlacek P, Riha P, Kodetova D, Bebrova E. Post-mortem analysis of Candida albicans breakthrough infection during echinocandin treatment in haematopoietic stem cell transplant recipient. Epidemiol Mikrobiol Imunol 2014; 63: 121–124.
19. Kanafani ZA, Perfect JR. Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact. Clin Infect Dis 2008; 46: 120–128.
20. Snelders E, Huis In't RA Veld, Rijs AJ, Kema GH, Melchers WJ, Verweij PE. Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles. Appl Environ Microbiol 2009; 75: 4053–4057.
21. Romani L. Immunity to fungal infections. Nat Rev Immunol 2011; 11: 275–288.
22. Blumental S, Mouy R, Mahlaoui N, Bougnoux ME, Debre M, Beaute J et al. Invasive mold infections in chronic granulomatous disease: a 25-year retrospective survey. Clin Infect Dis 2011; 53: e159–e169.
23. Wiley JM, Smith N, Leventhal BG, Graham ML, Strauss LC, Hurwitz CA et al. Invasive fungal disease in pediatric acute leukemia patients with fever and neutropenia during induction chemotherapy: a multivariate analysis of risk factors. J Clin Oncol 1990; 8: 280–286.
24. Bouzani M, Ok M, McCormick A, Ebel F, Kurzai O, Morton CO et al. Human NK cells display important antifungal activity against Aspergillus fumigatus, which is directly mediated by IFN-gamma release. J Immunol 2011; 187: 1369–1376.
25. Ma LL, Wang CL, Neely GG, Epelman S, Krensky AM, Mody CH. NK cells use perforin rather than granulysin for anticryptococcal activity. J Immunol 2004; 173: 3357–3365.
26. Morrison BE, Park SJ, Mooney JM, Mehrad B. Chemokine-mediated recruitment of NK cells is a critical host defense mechanism in invasive aspergillosis. J Clin Invest 2003; 112: 1862–1870.
27. Park SJ, Hughes MA, Burdick M, Strieter RM, Mehrad B. Early NK cell-derived IFN-{gamma} is essential to host defense in neutropenic invasive aspergillosis. J Immunol 2009; 182: 4306–4312.
28. Marukutira T, Huprikar S, Azie N, Quan SP, Meier-Kriesche HU, Horn DL. Clinical characteristics and outcomes in 303 HIV-infected patients with invasive fungal infections: data from the Prospective Antifungal Therapy Alliance registry, a multicenter, observational study. HIV/AIDS 2014; 6: 39–47.
29. Nagai H, Guo J, Choi H, Kurup V. Interferon-gamma and tumor necrosis factor-alpha protect mice from invasive aspergillosis. J Infect Dis 1995; 172: 1554–1560.
30. Roilides E, Dimitriadou-Georgiadou A, Sein T, Kadiltsoglou I, Walsh TJ. Tumor necrosis factor alpha enhances antifungal activities of polymorphonuclear and mononuclear phagocytes against Aspergillus fumigatus. Infect Immun 1998; 66: 5999–6003.
31. Gaundar SS, Clancy L, Blyth E, Meyer W, Gottlieb DJ. Robust polyfunctional T-helper 1 responses to multiple fungal antigens from a cell population generated using an environmental strain of Aspergillus fumigatus. Cytotherapy 2012; 14: 1119–1130.
32. Cenci E, Mencacci A, Bacci A, Bistoni F, Kurup VP, Romani L. T cell vaccination in mice with invasive pulmonary aspergillosis. J Immunol 2000; 165: 381–388.
33. Beck O, Koehl U, Tramsen L, Mousset S, Latge JP, Muller K et al. Enumeration of functionally active anti-Aspergillus T-cells in human peripheral blood. J Immunol Methods 2008; 335: 41–45.
34. Huang W, Na L, Fidel PL, Schwarzenberger P. Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice. J Infect Dis 2004; 190: 624–631.
35. Conti HR, Shen F, Nayyar N, Stocum E, Sun JN, Lindemann MJ et al. Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. J Exp Med 2009; 206: 299–311.
36. Nanjappa SG, Heninger E, Wuthrich M, Sullivan T, Klein B. Protective antifungal memory CD8(+) T cells are maintained in the absence of CD4(+) T cell help and cognate antigen in mice. J Clin Invest 2012; 122: 987–999.
37. Carvalho A, De Luca A, Bozza S, Cunha C, D'Angelo C, Moretti S et al. TLR3 essentially promotes protective class I-restricted memory CD8(+) T-cell responses to Aspergillus fumigatus in hematopoietic transplanted patients. Blood 2012; 119: 967–977.
38. Armstrong-James D, Harrison TS. Immunotherapy for fungal infections. Curr Opin Microbiol 2012; 15: 434–439.
39. Hebart H, Bollinger C, Fisch P, Sarfati J, Meisner C, Baur M et al. Analysis of T-cell responses to Aspergillus fumigatus antigens in healthy individuals and patients with hematologic malignancies. Blood 2002; 100: 4521–4528.
40. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004; 38: 1261–1265.
41. Mehrad B, Strieter RM, Standiford TJ. Role of TNF-alpha in pulmonary host defense in murine invasive aspergillosis. J Immunol 1999; 162: 1633–1640.
42. Gozalbo D, Maneu V, Gil ML. Role of IFN-gamma in immune responses to Candida albicans infections. Front Biosci 2014; 19: 1279–1290.
43. Perruccio K, Tosti A, Burchielli E, Topini F, Ruggeri L, Carotti A et al. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood 2005; 106: 4397–4406.
44. Jolink H, Hagedoorn RS, Lagendijk EL, Drijfhout JW, van Dissel JT, Falkenburg JH et al. Induction of A. fumigatus-specific CD4-positive T cells in patients recovering from invasive aspergillosis. Haematologica 2014; 99: 1255–1263.
45. Husain S, Alexander BD, Munoz P, Avery RK, Houston S, Pruett T et al. Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi. Clin Infect Dis 2003; 37: 221–229.
46. Tramsen L, Schmidt S, Boenig H, Latge JP, Lass-Florl C, Roeger F et al. Clinical-scale generation of multi-specific anti-fungal T cells targeting CandidaAspergillus and mucormycetes. Cytotherapy 2013; 15: 344–351.
47. Stuehler C, Khanna N, Bozza S, Zelante T, Moretti S, Kruhm M et al. Cross-protective TH1 immunity against Aspergillus fumigatus and Candida albicans. Blood 2011; 117: 5881–5891.
48. Bacci A, Montagnoli C, Perruccio K, Bozza S, Gaziano R, Pitzurra L et al. Dendritic cells pulsed with fungal RNA induce protective immunity to Candida albicans in hematopoietic transplantation. J Immunol 2002; 168: 2904–2913.
49. Cenci E, Mencacci A, Fe d'Ostiani C, Del Sero G, Mosci P, Montagnoli C et al. Cytokine- and T helper-dependent lung mucosal immunity in mice with invasive pulmonary aspergillosis. J Infect Dis 1998; 178: 1750–1760.
50. Bozza S, Perruccio K, Montagnoli C, Gaziano R, Bellocchio S, Burchielli E et al. A dendritic cell vaccine against invasive aspergillosis in allogeneic hematopoietic. Blood 2003; 102: 3807–3814.
51. Bacher P, Kniemeyer O, Teutschbein J, Thon M, Vodisch M, Wartenberg D et al. Identification of immunogenic antigens from Aspergillus fumigatus by direct multiparameter characterization of specific conventional and regulatory CD4+ T cells. J Immunol 2014; 193: 3332–3343.
52. Potenza L, Vallerini D, Barozzi P, Riva G, Forghieri F, Beauvais A et al. Characterization of specific immune responses to different Aspergillus antigens during the course of invasive aspergillosis in hematologic patients. PLoS One 2013; 8: e74326.
53. Jolink H, Meijssen IC, Hagedoorn RS, Arentshorst M, Drijfhout JW, Mulder A et al. Characterization of the T-cell-mediated immune response against the Aspergillus fumigatus proteins Crf1 and catalase 1 in healthy individuals. J Infect Dis 2013; 208: 847–856.
54. Braedel S, Radsak M, Einsele H, Latge JP, Michan A, Loeffler J et al. Aspergillus fumigatus antigens activate innate immune cells via toll-like receptors 2 and 4. Br J Haematol 2004; 125: 392–399.
55. Beck O, Topp MS, Koehl U, Roilides E, Simitsopoulou M, Hanisch M et al. Generation of highly purified and functionally active human TH1 cells against Aspergillus fumigatus. Blood 2006; 107: 2562–2569.
56. Stuehler C, Nowakowska J, Bernardini C, Topp MS, Battegay M, Passweg J et al. Multispecific Aspergillus T cells selected by CD137 or CD154 induce protective immune responses against the most relevant mold infections. J Infect Dis. 2014; 211: 1251–1261.
57. Tramsen L, Koehl U, Tonn T, Latge JP, Schuster FR, Borkhardt A et al. Clinical-scale generation of human anti-Aspergillus T cells for adoptive immunotherapy. Bone Marrow Transplant 2009; 43: 13–19.
58. Khanna N, Stuehler C, Conrad B, Lurati S, Krappmann S, Einsele H et al. Generation of a multipathogen-specific T-cell product for adoptive immunotherapy based on activation-dependent expression of CD154. Blood 2011; 118: 1121–1131.
59. Kumaresan PR, Manuri PR, Albert ND, Maiti S, Singh H, Mi T et al. Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection. Proc Natl Acad Sci USA 2014; 111: 10660–10665.
60. Straathof KC, Pule MA, Yotnda P, Dotti G, Vanin EF, Brenner MK et al. An inducible caspase 9 safety switch for T-cell therapy. Blood 2005; 105: 4247–4254.
61. Vogler I, Newrzela S, Hartmann S, Schneider N, von Laer D, Koehl U et al. An improved bicistronic CD20/tCD34 vector for efficient purification and in vivo depletion of gene-modified T cells for adoptive immunotherapy. Mol Ther 2010; 18: 1330–1338.
62. Wang X, Chang WC, Wong CW, Colcher D, Sherman M, Ostberg JR et al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood 2011; 118: 1255–1263.
63. Tramsen L, Schmidt S, Roeger F, Schubert R, Salzmann-Manrique E, Latge JP et al. Immunosuppressive compounds exhibit particular effects on functional properties of human anti-Aspergillus Th1 cells. Infect Immun 2014; 82: 2649–2656.
64. Feuchtinger T, Matthes-Martin S, Richard C, Lion T, Fuhrer M, Hamprecht K et al. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol 2006; 134: 64–76.
65. Peggs KS, Verfuerth S, Pizzey A, Chow SL, Thomson K, Mackinnon S. Cytomegalovirus-specific T cell immunotherapy promotes restoration of durable functional antiviral immunity following allogeneic stem cell transplantation. Clin Infect Dis 2009; 49: 1851–1860.
66. Blyth E, Clancy L, Simms R, Ma CK, Burgess J, Deo S et al. Donor-derived CMV specific T-cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation. Blood 2013; 121: 3745–3758.
67. Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010; 115: 925–935.
68. Khanna R, Bell S, Sherritt M, Galbraith A, Burrows SR, Rafter L et al. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc Natl Acad Sci USA 1999; 96: 10391–10396.
69. Louis CU, Straathof K, Bollard CM, Ennamuri S, Gerken C, Lopez TT et al. Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J Immunother 2010; 33: 983–990.